Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

What 4 Analyst Ratings Have To Say About RadNet

Author: Benzinga Insights | March 28, 2024 02:00pm

In the latest quarter, 4 analysts provided ratings for RadNet (NASDAQ:RDNT), showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 0 1 0 0
Last 30D 1 0 0 0 0
1M Ago 2 0 1 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.0, a high estimate of $58.00, and a low estimate of $48.00. This current average reflects an increase of 13.56% from the previous average price target of $46.67.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of RadNet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
David Macdonald Truist Securities Raises Buy $55.00 $51.00
Brian Tanquilut Jefferies Raises Buy $58.00 $47.00
Andrew Mok Barclays Announces Equal-Weight $48.00 -
David Macdonald Truist Securities Raises Buy $51.00 $42.00

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RadNet. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RadNet compared to the broader market.
  • Price Targets: Analysts predict movements in price targets, offering estimates for RadNet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of RadNet's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on RadNet analyst ratings.

Unveiling the Story Behind RadNet

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

RadNet's Economic Impact: An Analysis

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: RadNet displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 9.51%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.44%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): RadNet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.3%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): RadNet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.07%, the company showcases efficient use of assets and strong financial health.

Debt Management: RadNet's debt-to-equity ratio surpasses industry norms, standing at 2.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: What Are They?

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: RDNT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist